The great thing about immunotherapy is that it is so specific. Only the cells that need to be destroyed are attacked.​

The more general a treatment is, the more side effects it has, including collateral damage, as is the case with chemotherapy. Even more specific target therapies present the problem that many structures that occur in tumour cells are also present in normal cells and are thus also exposed to the destructive attack. With our specific treatment, this effect does not occur.​

A further feature of our therapy is that some of the immune cells migrate to the bone marrow and form an immunological memory. This can prevent the formation of metastases, which often remain undetected in the early stages. As soon as the tumour cells become active again, the immune system is able to control their growth.

 

Concerning the new checkpoint inhibitor antibody immunotherapies, the IOZK therapy can provide better conditions for their effectiveness. A prerequisite for this new form of therapy is a reaction of the immune system against the tumour growth, which is missing in most patients. The specific immunotherapy of the IOZK can produce an immune response and thus enable the fight against the tumour cells.

IMMUNOTHERAPY

The great thing about immunotherapy is that it is so specific. Only the cells that need to be destroyed are attacked.​

The more general a treatment is, the more side effects it has, including collateral damage, as is the case with chemotherapy. Even more specific target therapies present the problem that many structures that occur in tumor cells are also present in normal cells and are thus also exposed to the destructive attack. With our specific treatment, this effect does not occur.​

A further feature of our therapy is that some of the immune cells migrate to the bone marrow and form an immunological memory. This can prevent the formation of metastases, which often remain undetected in the early stages. As soon as the tumor cells become active again, the immune system is able to control their growth.

 

Concerning the new checkpoint inhibitor antibody immunotherapies, the IOZK therapy can provide better conditions for their effectiveness. A prerequisite for this new form of therapy is a reaction of the immune system against the tumor growth, which is missing in most patients. The specific immunotherapy of the IOZK can produce an immune response and thus enable the fight against the tumor cells.

de   eng